They need virtual partners to handle the screening, coaching, and day-to-day management of patients
Orforglipron is projected to generate about $1.6 billion in revenue in 2026, compared with $11.4 billion for Wegovy, which itself is seen easing from roughly $12.4 billion in 2025 as competition intensifies
To address this therapeutic gap, we have developed MEDI4166, a novel glucagon-like peptide-1 (GLP-1) receptor agonist peptide fused to a proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralising antibody that allows for glycaemic control and low-density lipoprotein cholesterol (LDL-C) lowering in a single molecule
(2) This sustained release mechanism can lead to more consistent and pronounced effects on muscle growth and recovery, making it a valuable tool in the bodybuilding arsenal
Discover the science behind BPC 157 and how it works its magic on the body's natural healing processes
Making poor food choices increases these common GLP-1 side effects: Nausea and vomiting: fatty or spicy foods irritate your digestive system, causing nausea
